DK3198009T3 - Onkolytiske tumorvira og anvendelsesfremgangsmåder - Google Patents

Onkolytiske tumorvira og anvendelsesfremgangsmåder Download PDF

Info

Publication number
DK3198009T3
DK3198009T3 DK15843893.7T DK15843893T DK3198009T3 DK 3198009 T3 DK3198009 T3 DK 3198009T3 DK 15843893 T DK15843893 T DK 15843893T DK 3198009 T3 DK3198009 T3 DK 3198009T3
Authority
DK
Denmark
Prior art keywords
methods
tumor viruses
oncolytic
oncolytic tumor
viruses
Prior art date
Application number
DK15843893.7T
Other languages
English (en)
Inventor
Clodagh O'shea
Shigeki Miyake-Stoner
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Application granted granted Critical
Publication of DK3198009T3 publication Critical patent/DK3198009T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15843893.7T 2014-09-24 2015-09-23 Onkolytiske tumorvira og anvendelsesfremgangsmåder DK3198009T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462054724P 2014-09-24 2014-09-24
PCT/US2015/051745 WO2016049201A1 (en) 2014-09-24 2015-09-23 Oncolytic tumor viruses and methods of use

Publications (1)

Publication Number Publication Date
DK3198009T3 true DK3198009T3 (da) 2021-11-22

Family

ID=55581955

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15843893.7T DK3198009T3 (da) 2014-09-24 2015-09-23 Onkolytiske tumorvira og anvendelsesfremgangsmåder

Country Status (11)

Country Link
US (1) US12514887B2 (da)
EP (2) EP3198009B1 (da)
JP (3) JP6764859B2 (da)
KR (3) KR102814615B1 (da)
CN (1) CN108064275A (da)
AU (3) AU2015320665B2 (da)
CA (1) CA2961748A1 (da)
DK (1) DK3198009T3 (da)
ES (1) ES2899913T3 (da)
PL (1) PL3198009T3 (da)
WO (1) WO2016049201A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
PL3198009T3 (pl) * 2014-09-24 2022-01-24 Salk Institute For Biological Studies Onkolityczne wirusy nowotworowe i sposoby zastosowania
ES2837400T3 (es) * 2015-10-05 2021-06-30 Salk Inst For Biological Studi Adenovirus sintético con tropismo para los tejidos dañados para su uso en la promoción de la reparación de heridas y regeneración tisular
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja) * 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2018111767A1 (en) * 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2018125970A1 (en) * 2016-12-30 2018-07-05 Salk Institute For Biological Studies Synthetic adenoviruses targeting bone tissue and uses thereof
US20190352616A1 (en) * 2017-01-30 2019-11-21 Epicentrx, Inc. Multiple transgene recombinant adenovirus
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
US12295976B2 (en) 2018-03-28 2025-05-13 Epicentrx, Inc. Personalized cancer vaccines
JP7430395B2 (ja) * 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
CN111363726A (zh) * 2018-12-26 2020-07-03 上海元宋生物技术有限公司 表达干扰素的溶瘤病毒及其应用
CN113710810A (zh) * 2019-02-21 2021-11-26 安利舒免疫溶瘤技术公司 溶瘤腺病毒载体和使用方法
WO2021044061A1 (en) * 2019-09-05 2021-03-11 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
EP3812465A1 (en) * 2019-10-21 2021-04-28 Universität Ulm Adenovirus comprising a modified adenovirus hexon protein
CN115515588A (zh) 2020-02-14 2022-12-23 萨克生物研究学院 大环ulk1/2抑制剂
AU2021218739A1 (en) * 2020-02-14 2022-09-22 Salk Institute For Biological Studies Inhibitors of ULK1/2 and methods of using same
EP4175655A4 (en) * 2020-07-06 2024-11-27 Salk Institute for Biological Studies ONCOLYTIC ADENOVIRUS WITH REPLICATION SELECTIVITY BASED ON THE STATE OF P53 TRANSCRIPTIONAL ACTIVITY
US20240247283A1 (en) * 2021-05-06 2024-07-25 Asimov Inc. Compositions and methods for adeno-associated viral production

Family Cites Families (334)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
DK0931830T3 (da) 1993-02-16 2001-06-11 Onyx Pharma Inc Cytopatiske vira til terapi og profylakse af neoplasi
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US7045347B2 (en) 1993-06-24 2006-05-16 Advec, Inc. Helper dependent adenovirus vectors based on integrase family site-specific recombinases
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US20010006629A1 (en) 1993-10-25 2001-07-05 Richard J. Gregory Recombinant adenoviral vector and methods of use
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5962311A (en) 1994-09-08 1999-10-05 Genvec, Inc. Short-shafted adenoviral fiber and its use
FR2726285B1 (fr) 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
CA2206683A1 (en) 1994-12-12 1996-06-20 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
AUPN477695A0 (en) 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US5945335A (en) 1995-11-09 1999-08-31 Avigen, Inc. Adenovirus helper-free system for producing recombinant AAV virions lacking oncogenic sequences
JP2000500020A (ja) 1995-11-13 2000-01-11 コミサリア・ア・レネルジー・アトミーク 正十二面体様アデノウイルス・タンパク質複合体、それを含む組成物、及びその使用方法
JP3420586B2 (ja) 1995-11-28 2003-06-23 ジェンベク、インコーポレイティッド 細胞への遣伝子導入のためのベクターおよび方法
US6133243A (en) 1996-02-22 2000-10-17 Onyx Pharmaceuticals, Inc. Liposomal-viral DNA complexes for treating disease
FR2746110B1 (fr) 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
CZ438398A3 (cs) 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US20050287120A1 (en) 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
NZ501140A (en) 1997-05-28 2001-07-27 Genvec Inc Adenoviral fiber trimer with reduced affinity for native cell surface receptors
US6200799B1 (en) 1997-06-03 2001-03-13 University Of Lausanne Somatic gene therapy to suppress secondary cataract formation following eye surgery
ATE256196T1 (de) 1997-06-09 2003-12-15 Genvec Inc Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
CN1281512A (zh) 1997-12-12 2001-01-24 昂尼克斯药物公司 p53+肿瘤细胞的选择性杀伤和诊断
EP1053013A4 (en) 1998-02-06 2004-12-22 Uab Research Foundation ADENOVIRUS VECTOR CONTAINING A HETEROLOGICAL PEPTIDEPITOP IN THE HI LOOP OF THE FIBER BUTTON
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
ATE342350T1 (de) 1998-02-17 2006-11-15 Uab Research Foundation Modifizierte adenoviren welche ein faserersatzprotein enthalten
US20050095231A1 (en) 1998-02-17 2005-05-05 Curiel David T. Modified adenovirus containing a fiber replacement protein
AU2796799A (en) 1998-03-03 1999-09-20 Uab Research Foundation, The Amplification of gene transfer and gene therapy by controlled replication
WO1999047180A1 (en) 1998-03-20 1999-09-23 Genzyme Corporation Chimeric adenoviral vectors for targeted gene delivery
US7829329B2 (en) 1998-04-24 2010-11-09 Onyx Pharmaceuticals, Inc. Adenoviral vectors for treating disease
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ES2180258T3 (es) 1998-07-07 2003-02-01 Transgene Sa Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
KR20020013464A (ko) 1998-08-27 2002-02-20 추후제출 이종 유전자의 전달을 위한 표적화된 아데노바이러스 벡터
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
US6841540B1 (en) 1998-09-29 2005-01-11 The Uab Research Foundation Immunomodulation by genetic modification of dendritic cells and B cells
SK4412001A3 (en) 1998-10-15 2001-12-03 Canji Inc Selectively replicating viral vectors
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1141357A1 (en) 1999-01-14 2001-10-10 Novartis AG Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6395875B1 (en) 1999-01-25 2002-05-28 Brookhaven Science Associates Llc Recombinant soluble adenovirus receptor
US7157266B2 (en) 1999-01-25 2007-01-02 Brookhaven Science Associates Llc Structure of adenovirus bound to cellular receptor car
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
ATE403006T1 (de) 1999-03-04 2008-08-15 Crucell Holland Bv Verwendung eines adenovirusvektors zur transduktion von synovialen zellen
US6824771B1 (en) 1999-05-12 2004-11-30 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
ES2372823T3 (es) 1999-05-17 2012-01-26 Crucell Holland B.V. Adenovirus recombinante del serotipo ad11.
US20050232900A1 (en) 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
AU5464000A (en) 1999-06-01 2000-12-18 University Of Washington Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
EP1593742A3 (en) 1999-06-01 2006-02-01 The University of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
DE19929569A1 (de) 1999-06-21 2000-12-28 Holm Per Sonne Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1
AU763733B2 (en) 1999-07-06 2003-07-31 Got-A-Gene Ab Recombinant adenovirus
US7589069B1 (en) 1999-07-12 2009-09-15 Saint Louis University Replication-competent anti-cancer vectors
WO2001016344A1 (fr) 1999-08-27 2001-03-08 Transgene S.A. Fibre adenovirale modifiee et utilisations
WO2001021217A2 (en) 1999-09-23 2001-03-29 Genvec, Inc. Method of treating cells of the prostate prophylactically or therapeutically
ATE345819T1 (de) 1999-09-24 2006-12-15 Uab Research Foundation Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung
AU1190901A (en) 1999-09-30 2001-04-30 Trustees Of The University Of Pennsylvania, The Replication selective adenoviruses for use in cancer therapy
CA2386626A1 (en) 1999-10-15 2001-04-26 Richard Murphy Targeted vectors
CA2720361A1 (en) 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
AU776061B2 (en) 1999-11-15 2004-08-26 Onyx Pharmaceuticals An oncolytic adenovirus
US6867022B1 (en) 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US6740525B2 (en) 2000-02-09 2004-05-25 Genvec, Inc. Adenoviral capsid containing chimeric protein IX
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
EP1266022B1 (en) 2000-03-24 2008-10-22 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US20030082146A1 (en) 2000-04-26 2003-05-01 Van Es Helmuth H. G. Adenovirus vectors with knobless fibers, and their uses
EP1280929A2 (en) 2000-05-01 2003-02-05 Novartis AG Vectors for ocular transduction and use thereof for genetic therapy
US7332337B2 (en) 2000-05-16 2008-02-19 Galapagos Nv Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
EP1157999A1 (en) 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
CN1293196C (zh) 2000-05-26 2007-01-03 大日本住友制药株式会社 具有副作用降低的特性的新型重组腺病毒载体
CA2410665C (en) 2000-05-31 2017-11-07 University Of Saskatchewan Modified bovine adenovirus having altered tropism
AU2001265154A1 (en) 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
US7754201B2 (en) 2000-06-02 2010-07-13 GenPhar, Inc Method of vaccination through serotype rotation
EP1167533A1 (en) 2000-06-23 2002-01-02 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Methods and means for the complementation of viral protein expression in stable cell lines
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US20020106382A1 (en) 2000-07-14 2002-08-08 Young Charles S.H. Modified adenovirus and uses thereof
US7022496B2 (en) 2000-07-14 2006-04-04 The Johns Hopkins University Use of gene product of adenovirus early region 4 ORF-6 to inhibit repair of double-strand breaks in DNA
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
ES2256302T3 (es) 2000-08-10 2006-07-16 Crucell Holland B.V. Vectores adenovirales para la transduccion de condrocitos.
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
JP4394878B2 (ja) 2000-12-08 2010-01-06 ライフ テクノロジーズ コーポレーション 複数の認識部位を用いた核酸分子合成のための方法および組成物
US20030095989A1 (en) 2000-12-18 2003-05-22 Irving John M. Chimeric cytolytic viruses for cancer treatment
US6635466B2 (en) 2001-01-09 2003-10-21 University Of Iowa Research Foundation Adenovirus serotype 30 (Ad30)
WO2002064746A2 (en) 2001-02-14 2002-08-22 Uab Research Foundation Combined transductional and transcriptional targeting system for improved gene delivery
IL152420A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
JP2005525779A (ja) 2001-04-02 2005-09-02 バイエル アクチェンゲゼルシャフト 核酸構築物のトランスフェクションによって、身体サンプルから細胞を特異的に検出、単離および特徴付けするための方法
US20030219899A1 (en) 2001-04-17 2003-11-27 Nikolay Korokhov Mosaic adenoviral vectors
WO2002083880A1 (en) 2001-04-17 2002-10-24 Vectorlogics, Inc. Mosaic adenoviral vectors
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
AU2002322285A1 (en) 2001-06-22 2003-01-08 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
US6844192B2 (en) 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
AU2002346084B2 (en) 2001-07-23 2006-11-16 Onyx Pharmaceuticals, Inc. Viral mutants that selectively replicate in targeted human cancer cells
EP1427816A4 (en) 2001-09-18 2004-12-01 Clontech Lab Inc METHOD FOR THE PRODUCTION OF ADENOVIRUS VECTORS, BASED ON A SPECIFIC RECOMBINASE
US7569217B2 (en) 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
AU2002343901A1 (en) 2001-09-29 2003-04-14 Kim, Joo-Hang Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
CN100475966C (zh) 2001-11-23 2009-04-08 上海三维生物技术有限公司 具有肿瘤细胞特异性感染和转基因表达能力的新型腺病毒
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
CA2474763A1 (en) 2002-01-24 2003-07-31 The Scripps Research Institute Fiber shaft modifications for efficient targeting
EP1470233A1 (en) 2002-02-01 2004-10-27 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
US20040005710A1 (en) 2002-03-09 2004-01-08 Ho-Sun Son Method for producing recombinant viruses using site-specific recombination
DK1498129T3 (da) 2002-03-26 2006-04-03 Oncolytics Biotech Inc Anvendelse af adenovirusser, muteret i VA generne, til cancerbehandling
PL215165B1 (pl) 2002-04-25 2013-10-31 Crucell Holland Bv Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego
WO2003092579A2 (en) 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
US7094399B2 (en) 2002-05-08 2006-08-22 Intronn, Inc. Use of spliceosome mediated RNA trans-splicing to confer cell selective replication to adenoviruses
US20060099178A1 (en) 2002-05-27 2006-05-11 Holm Per S Novel use of adenoviruses and nucleic acids coding therefor
CA2491805A1 (en) 2002-07-10 2004-01-22 Transgene S.A. Modified adenoviral fiber with ablated binding to cellular receptors
US20040219516A1 (en) 2002-07-18 2004-11-04 Invitrogen Corporation Viral vectors containing recombination sites
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
WO2004018627A2 (en) 2002-08-22 2004-03-04 Merck & Co., Inc. Methods for propagating adenovirus and virus produced thereby
EP1545627A4 (en) 2002-10-01 2006-12-27 Univ Duke TARGETED TUMOR THERAPY THROUGH THE USE OF RECOMBINANT ADENOVIRUS VECTORS FOR SELECTIVE REPLICATION IN HYPOXIC TUMOR REGIONS
EP1413586A1 (en) 2002-10-21 2004-04-28 Centre National De La Recherche Scientifique (Cnrs) Regulation of the Cre recombinase using a dissociation/re-association system of said recombinase
US20040102382A1 (en) 2002-11-27 2004-05-27 Transgene, S.A. Targeting peptides
WO2004083418A1 (en) 2003-03-17 2004-09-30 Merck & Co., Inc. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
US20040191761A1 (en) 2003-03-27 2004-09-30 Routes John M. Modified adenoviral E1A constructs and methods of use thereof
CN1759177A (zh) 2003-03-28 2006-04-12 麦克公司 腺病毒血清型34载体,核酸及其由此产生的病毒
CA2519680A1 (en) 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
US20050095705A1 (en) 2003-04-15 2005-05-05 Michael Kadan Method for production of oncolytic adenoviruses
US20060281090A1 (en) 2003-05-01 2006-12-14 University Of Washington Uw Tech Transfer- Invention Licensing Capsid-modified adenovirus vectors and methods of using the same
AU2004238979B2 (en) 2003-05-14 2008-12-18 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Broadening adenovirus tropism
US20050079158A1 (en) 2003-06-05 2005-04-14 Shenzhen Allucks Biotech Co., Ltd. Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof
EP1631582A2 (en) 2003-06-10 2006-03-08 University of Saskatchewan Chimeric adenovirus capsid proteins
US20070003923A1 (en) 2003-06-11 2007-01-04 Scripps Research Institute, The Modified fiber proteins for efficient receptor binding
US7491508B2 (en) 2003-06-20 2009-02-17 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
CA2527369A1 (en) 2003-07-18 2005-02-03 Onyx Pharmaceuticals, Inc. Subgroup b adenoviral vectors for treating disease
ES2391975T3 (es) 2003-07-25 2012-12-03 Genvec, Inc. Vacunas a base de vector adenovírico
WO2005030261A1 (en) 2003-08-28 2005-04-07 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
US20050186178A1 (en) 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
EP1664099A2 (en) 2003-09-09 2006-06-07 Niels Rudi Pedersen Adenoviral epitopes
US7482156B2 (en) 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
EP1689445B1 (de) 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
US20050201978A1 (en) 2003-11-17 2005-09-15 Lipton James S. Tumor and infectious disease therapeutic compositions
EP1702071B1 (en) * 2003-12-31 2012-02-22 Kalobios Inc. Transactivation system for mammalian cells
WO2005075506A1 (en) 2004-01-09 2005-08-18 The Scripps Research Institute Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors
SI2163260T1 (sl) 2004-01-23 2017-07-31 Msd Italia S.R.L. Nosilci šimpanzjih adenovirusnih cepiv
US20050201936A1 (en) 2004-02-12 2005-09-15 Wold William S.M. Models for viral-based cancer therapy
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
WO2006075819A1 (en) 2004-03-30 2006-07-20 Industry-Academic Cooperation Foundation, Yonsei University Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US20080292592A1 (en) 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
EP1743041B1 (en) 2004-05-03 2012-06-27 Stefan Kochanek Modified viral vector particles
GB0411428D0 (en) 2004-05-21 2004-06-23 Got A Gene Ab Vectors
WO2005118825A2 (en) 2004-05-26 2005-12-15 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
US20050271622A1 (en) 2004-06-03 2005-12-08 Shenzhen Allucks Biotech Co., Ltd. Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof
WO2005117993A2 (en) 2004-06-04 2005-12-15 Genvec, Inc. Method of using adenoviral vectors with improved safety and efficacy for the treatment of cancer
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
GB0416487D0 (en) 2004-07-23 2004-08-25 Isis Innovation Modified virus
US7776322B2 (en) 2004-08-16 2010-08-17 Stefan Kochanek Modified viral vector particles
JP2008511336A (ja) 2004-09-01 2008-04-17 アメリカ合衆国 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
US7943373B2 (en) 2004-09-29 2011-05-17 Oncolys Biopharma, Inc. Telomelysin/GFP-expressing recombinant virus
BRPI0516048A (pt) 2004-10-13 2008-08-19 Crucell Holland B V E Beth Isr batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c
US20070122817A1 (en) 2005-02-28 2007-05-31 George Church Methods for assembly of high fidelity synthetic polynucleotides
CN101090912A (zh) 2004-10-25 2007-12-19 诺瓦提斯公司 Torc多核苷酸和多肽以及使用方法
IL166049A0 (en) 2004-12-30 2006-01-15 Gavish Galilee Bio Appl Ltd Method for obtaining modified proteins and viruseswith intact native binding
WO2006070024A2 (de) 2004-12-31 2006-07-06 Per Sonne Holm E1 -minus adenoviren und deren verwendung
CN101128593B (zh) 2004-12-31 2014-09-03 佩尔·松内·霍尔姆 逆转动物细胞中多种抗性的方法
WO2006086357A2 (en) 2005-02-10 2006-08-17 Merck & Co., Inc. Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
WO2006086284A2 (en) 2005-02-11 2006-08-17 Merck & Co., Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
KR100747646B1 (ko) 2005-02-25 2007-08-08 연세대학교 산학협력단 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
WO2006119449A2 (en) 2005-05-04 2006-11-09 Vectorlogics, Inc. Modified adenovirus containing a stabilized antibody
WO2007050128A2 (en) 2005-05-31 2007-05-03 Vectorlogics, Inc. Shielded adenoviral vectors and methods of use
JP5475279B2 (ja) 2005-06-17 2014-04-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｃ型肝炎ウイルス核酸ワクチン
AU2006284756B2 (en) 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
KR100723009B1 (ko) 2005-11-30 2007-05-29 한국원자력연구원 인간 ｐ３１ 유전자를 함유하는 악성 종양 치료용 약학적조성물
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
WO2007094653A1 (en) 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
US20070292396A1 (en) 2006-03-02 2007-12-20 Juan Fueyo Combination therapy with oncolytic adenovirus
US20070292954A1 (en) 2006-04-21 2007-12-20 The Brigham And Women's Hospital, Inc. Generation of recombinant DNA by sequence-and ligation-independent cloning
EP2012822B1 (en) 2006-04-28 2010-01-20 The Trustees of the University of Pennsylvania Modified adenovirus hexon protein and uses thereof
US20080242608A1 (en) 2006-06-02 2008-10-02 Azad Bonni Methods and compositions for treating and preventing neurologic disorders
US20090280089A1 (en) 2006-06-19 2009-11-12 Institut Gustave Roussy Inhibition of the liver tropism of adenoviral vectors
JP2008048621A (ja) 2006-08-22 2008-03-06 Chiba Prefecture キメラ型アデノウイルスとその作製方法並びにそれを用いた医薬
GR20060100496A (el) 2006-09-01 2008-04-15 Παρθενιος Μπουλικας ΛΙΠΟΣΩΜΑΤΙΚΑ ΕΓΚΑΨΥΛΙΩΜΕΝΟΙ ΦΟΡΕΙΣ-ΥΒΡΙΔΙΟΥ ΑΔΕΝΟΙΟΥ - ΙΟΥ SEMLIKI FOREST (SFV), ΠΟΥ ΦΕΡΕΙ ΚΑΤΑΣΚΕΥΑΣΜΑΤΑ RNAi ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΑ ΓΟΝΙΔΙΑ ΠΟΥ ΧΡΗΣΙΜΟΠΟΙΟΥΝΤΑΙ ΕΝΑΝΤΙΟΝ ΣΤΟΧΩΝ ΚΑΡΚΙΝΟΥ ΚΑΙ ΑΛΛΩΝ ΑΣΘΕΝΕΙΩΝ
WO2008067025A2 (en) 2006-09-29 2008-06-05 Evanston Northwestern Healthcare Oncolytic adenoviruses and uses thereof
WO2008140474A1 (en) 2006-10-26 2008-11-20 Johns Hopkins University Recombinant adenovirus vaccines
US8207180B2 (en) 2006-11-28 2012-06-26 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
WO2008095168A2 (en) 2007-02-01 2008-08-07 University Of Chicago Compositions and methods related to a recombinant adenoviral vector that targets il 13 receptors
JP5746823B2 (ja) 2007-03-14 2015-07-08 インスティトゥト カタラ ドンコロジア Ｅ３−１９ｋタンパク質の小胞体保持ドメインに突然変異を有するアデノウイルス及び癌治療におけるその用途
WO2008150496A2 (en) 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
WO2009065800A1 (en) 2007-11-20 2009-05-28 Crucell Holland B.V. Recombinant human adenoviruses for eliciting mucosal immune responses
PT2220242T (pt) 2007-11-28 2017-04-03 Univ Pennsylvania Adenovírus símio da subfamília b sadv-28,27,-29,-32,-33 e -35 e suas utilizações
KR101761691B1 (ko) 2007-11-28 2017-07-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
WO2009105084A2 (en) 2007-11-28 2009-08-27 The Trustees Of The University Of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
CN102014948A (zh) 2008-02-07 2011-04-13 安德鲁·贝克 腺病毒向性的调节
EP2250255A2 (en) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
WO2009117656A2 (en) 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
US20110086063A1 (en) 2008-06-04 2011-04-14 Cornell University Vaccines for prevention and treatment of addiction
BRPI0914223A2 (pt) 2008-06-19 2019-09-24 Millennium Pharm Inc derivados de tiofeno ou tiazol e seus usos como inibidores de p13k
KR101034811B1 (ko) 2008-08-25 2011-05-16 단국대학교 산학협력단 조직 특이적 프로모터와 암 특이 유전자를 타겟팅하는트랜스-스플라이싱 라이보자임을 포함하는 재조합아데노바이러스 및 이의 용도
US8808986B2 (en) 2008-08-27 2014-08-19 Gen9, Inc. Methods and devices for high fidelity polynucleotide synthesis
KR20110081222A (ko) 2008-09-26 2011-07-13 어번 유니버시티 비복제성 벡터화된 백신의 점막 투여에 의한 조류의 면역화
US8940290B2 (en) 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
US9345787B2 (en) 2008-12-22 2016-05-24 Targovax Oy Adenoviral vectors and methods and uses related thereto
JP2012513209A (ja) 2008-12-22 2012-06-14 オンコス セラピュティックス オサケ ユキチュア 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用
CA2749325C (en) 2009-02-02 2021-03-30 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
HUE046565T2 (hu) 2009-03-02 2020-03-30 Univ California Tumorszelektív adenovírus E1A és E1B mutánsok
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2010138675A1 (en) 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
KR20120052369A (ko) 2009-07-31 2012-05-23 팍스박스, 인코포레이티드 아데노바이러스계 벡터
WO2011022002A1 (en) 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
US9555089B2 (en) 2009-08-18 2017-01-31 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
KR101248912B1 (ko) 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
WO2011101869A1 (en) 2010-02-22 2011-08-25 Transgene Biotek Ltd. Adeno-associated virus 2/8 - micro rna-101 therapy for liver cancer
CN102191245B (zh) 2010-03-15 2013-11-13 浙江东方基因生物制品有限公司 应用肿瘤特异性启动子表达报告基因来检测循环血中肿瘤细胞的方法和试剂
EP2547362B1 (en) 2010-03-17 2021-08-25 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
WO2011129468A1 (en) 2010-04-14 2011-10-20 Mogam Biotechnology Research Institute Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same
WO2011133040A2 (en) 2010-04-23 2011-10-27 Orca Therapeutics B.V. Replication-competent adenoviruses
KR101497035B1 (ko) 2010-04-26 2015-02-27 주식회사 녹십자 종양 특이적 프로모터 및 이를 포함하는 종양살상 바이러스 벡터
JP6499825B2 (ja) 2010-06-10 2019-04-10 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション デスモグレイン２（ｄｓｇ２）とのアデノウイルスの相互作用のための方法およびシステム
US20140017668A1 (en) 2010-06-30 2014-01-16 The Johns Hopkins University COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING CIRCULATING TUMOR CELLS (CTCs)
CN103237889B (zh) 2010-08-16 2017-04-05 萨克生物研究学院 腺病毒组装方法
AU2011292119B2 (en) 2010-08-16 2015-06-11 Salk Institute For Biological Studies Anti-cancer adenoviruses
WO2012022496A2 (en) 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
BR112013006699A2 (pt) 2010-09-24 2016-06-14 Oncos Therapeutics Oy vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral
EP2619224A1 (en) 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
CN102174479B (zh) 2011-03-02 2013-04-03 北京锤特生物科技有限公司 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
WO2012132369A1 (ja) 2011-03-25 2012-10-04 国立大学法人鹿児島大学 癌幹細胞を標的とするウイルスベクター
US20140341857A1 (en) 2011-05-16 2014-11-20 Institut Gustave Roussy Combination of oncolytic adenoviruses with histone deacetylase inhibitors
CN103732249A (zh) 2011-05-23 2014-04-16 威斯特解剖及生物研究所 含有经修饰腺病毒载体的流感疫苗
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
CN102260712B (zh) 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
KR101946666B1 (ko) 2011-08-23 2019-02-11 고쿠리츠 켄큐 카이하츠 호진 이야쿠 키반 켄코 에이요 켄큐쇼 제한 증식형 아데노바이러스
US20140348791A1 (en) 2011-09-09 2014-11-27 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
CN107937440A (zh) 2011-10-05 2018-04-20 金维克有限公司 猴腺病毒(大猩猩)或腺病毒载体及其使用方法
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
WO2013090806A2 (en) 2011-12-15 2013-06-20 Washington University Porcine knob xenotype chimeric adenoviral vector for dendritic cell infection
US11155599B2 (en) 2012-02-02 2021-10-26 Board Of Regents, The University Of Texas System Adenoviruses expressing heterologous tumor-associated antigens
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
JP6170999B2 (ja) 2012-03-13 2017-07-26 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスおよび化学二量体を用いる選択細胞の標的化
EP2825889A4 (en) 2012-03-14 2015-10-28 Salk Inst For Biological Studi ADENOVIRAL TUMOR DIAGNOSIS
US9017672B2 (en) 2012-05-11 2015-04-28 Immunicum Aktiebolag Hexon Tat-PTD modified adenovirus and uses thereof
SG10201609511XA (en) 2012-05-18 2016-12-29 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
EP2855685B1 (en) 2012-05-24 2017-03-08 Janssen Vaccines & Prevention B.V. Adenoviral vectors for transduction of vascular tissue
WO2013181128A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Modified serotype 28 adenoviral vectors
AU2013203696A1 (en) 2012-06-25 2014-01-16 University Of Canberra Recombinant Viral Vectors and Uses Therefor
AU2013323775B2 (en) 2012-09-25 2018-10-18 University Of Washington Through Its Center For Commercialization Desmoglein 2 (DSG2) binding proteins and uses therefor
KR101429696B1 (ko) 2012-11-21 2014-08-13 국립암센터 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도
US20160090574A1 (en) 2013-02-28 2016-03-31 Psioxus Therapuetics Limited A process for the production of adenovirus
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
DK3461491T3 (da) 2013-04-18 2025-02-03 Tilt Biotherapeutics Oy Forbedret adoptiv celleterapi
EP3010519B1 (en) 2013-06-18 2021-04-07 Dnatrix Inc. Oncolytic adenovirus for use in a treatment of brain cancer
ES2638320T3 (es) 2013-09-24 2017-10-19 University Of Washington Through Its Center For Commercialization Proteínas de unión a desmogleina 2 (DSG2) y sus usos
KR20160137946A (ko) 2013-11-22 2016-12-02 디엔에이트릭스, 인코포레이티드 면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스
GB201415579D0 (en) 2014-09-03 2014-10-15 Psioxus Therapeutics Ltd A process
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
JP6705755B2 (ja) 2014-05-19 2020-06-03 バロ セラピューティクス オイＶａｌｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 癌ワクチン開発のための改変アデノウイルス
KR102365331B1 (ko) 2014-05-28 2022-02-22 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 Reic 유전자를 발현하는 제한 증식형 아데노바이러스
PL3198009T3 (pl) * 2014-09-24 2022-01-24 Salk Institute For Biological Studies Onkolityczne wirusy nowotworowe i sposoby zastosowania
US10617729B2 (en) 2014-12-24 2020-04-14 The Uab Research Foundation Multitargeting onocolytic adenovirus, methods of use, and methods of making
WO2016118433A1 (en) 2015-01-20 2016-07-28 Shayakhmetov Dmitry M Detargeted adenovirus variants and related methods
US20180051301A1 (en) 2015-03-02 2018-02-22 Washington University Induction of pacemaker-like cells from cardiomyocytes
AU2016232009B2 (en) 2015-03-17 2021-07-15 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
EP3072900A1 (en) 2015-03-27 2016-09-28 Medizinische Hochschule Hannover Anti-tumour medicament based on adenovirus
GB201505860D0 (en) 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
EP3329934B1 (en) 2015-09-01 2021-03-24 Genemedicine Co., Ltd. Antitumor immunity enhancing composition containing adenovirus simultaneously expressing il-12 and shvegf
ES2837400T3 (es) 2015-10-05 2021-06-30 Salk Inst For Biological Studi Adenovirus sintético con tropismo para los tejidos dañados para su uso en la promoción de la reparación de heridas y regeneración tisular
CN108135934B (zh) 2015-10-19 2024-09-10 永恒生物科技股份有限公司 通过组合疗法治疗实体或淋巴肿瘤的方法
US11246896B2 (en) 2015-10-28 2022-02-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Tumor-specific adenovirus vectors and therapeutic uses
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
ES3041500T3 (en) 2016-03-10 2025-11-12 Cg Oncology Inc Methods of treating solid tumors by combination therapy
US20170314044A1 (en) 2016-05-02 2017-11-02 Regents Of The University Of Minnesota Adenovirus constructs and methods
US20190201551A1 (en) 2016-05-23 2019-07-04 Washington University Pulmonary targeted cas9/crispr for in vivo editing of disease genes
CN109789177A (zh) 2016-05-27 2019-05-21 德那翠丝有限公司 腺病毒和免疫调节剂组合治疗
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
CA3038968A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
FI20165814A7 (fi) 2016-10-27 2018-04-28 Tilt Biotherapeutics Oy Interleukiini 8 (il-8) prognostisena ja ennustavana biomarkkerina ja koostumukset ja vektorit käytettäväksi onkolyyttisessa immunoterapiassa
US20190275092A1 (en) 2016-11-01 2019-09-12 Dnatrix, Inc. Combination therapy for treatment of brain cancers
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018091151A1 (en) 2016-11-17 2018-05-24 Vcn Biosciences Sl Use of viral vectors in the treatment of retinoblastoma
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CN110036020A (zh) 2016-12-09 2019-07-19 葛兰素史密丝克莱恩生物有限公司 具有狂犬病病毒抗原的黑猩猩腺病毒构建体
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2018125970A1 (en) 2016-12-30 2018-07-05 Salk Institute For Biological Studies Synthetic adenoviruses targeting bone tissue and uses thereof
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
MX2019008922A (es) 2017-01-30 2020-01-20 Epicentrx Inc Mutantes de la caja tata y de la caja caat selectivas de tumor.
US20190352616A1 (en) 2017-01-30 2019-11-21 Epicentrx, Inc. Multiple transgene recombinant adenovirus
CA3059605A1 (en) 2017-04-10 2018-10-18 Epicentrx, Inc. Method for producing recombinant virus
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
JP7260173B2 (ja) 2017-04-21 2023-04-18 ベイラー カレッジ オブ メディスン 腫瘍溶解性ウイルス療法および免疫療法
WO2018201017A1 (en) 2017-04-27 2018-11-01 Washington University Dendritic cell targeted adenovirus for vaccination
WO2018204677A1 (en) 2017-05-04 2018-11-08 Epicentrx, Inc. Oncolytic adenovirus formulation
CA3064892A1 (en) 2017-05-24 2018-11-29 Epicentrx, Inc. Anti-angiogenic adenovirus
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
EP3655539A1 (en) 2017-07-21 2020-05-27 GlaxoSmithKline Biologicals S.A. Chikungunya virus antigen constructs
EP3460052B1 (en) 2017-09-20 2019-10-30 Immunicum AB Improved allogeneic dendritic cells for use in cancer treatment
WO2019073059A1 (en) 2017-10-12 2019-04-18 Freeline Therapeutics Limited ADENOVIRAL AUXILIARY VIRUSES WITH DEFECTIVE CYCLE LIFE, PRODUCTION AND USE FOR THE PRODUCTION OF RAAV
EP3704139A1 (en) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
SG11202003200VA (en) 2017-10-31 2020-05-28 Janssen Vaccines & Prevention Bv Adenovirus and uses thereof
JP7366014B2 (ja) 2017-10-31 2023-10-20 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルス及びその用途
EP3704256A1 (en) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
GB201802539D0 (en) 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses
GB201804468D0 (en) 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
GB201804473D0 (en) 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
US12295976B2 (en) 2018-03-28 2025-05-13 Epicentrx, Inc. Personalized cancer vaccines
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
WO2019202118A1 (en) 2018-04-20 2019-10-24 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
CN112638936A (zh) 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
WO2020014539A1 (en) 2018-07-11 2020-01-16 Epicentrx, Inc. Methods and compositions for targeting cancer cells for treatment
US12233096B2 (en) 2018-08-31 2025-02-25 Orca Therapeutics B.V. Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (GSK3) and methods of killing aberrant cells
WO2020076820A2 (en) 2018-10-09 2020-04-16 Nikegen, Llc Compositions and methods for preparing viral vectors

Also Published As

Publication number Publication date
EP3198009A4 (en) 2018-09-05
AU2015320665B2 (en) 2022-06-16
JP7416423B2 (ja) 2024-01-17
PL3198009T3 (pl) 2022-01-24
KR20170063801A (ko) 2017-06-08
KR102608590B1 (ko) 2023-12-01
EP4043021A2 (en) 2022-08-17
ES2899913T3 (es) 2022-03-15
CA2961748A1 (en) 2016-03-31
AU2025203440A1 (en) 2025-06-05
WO2016049201A1 (en) 2016-03-31
KR102814615B1 (ko) 2025-05-28
AU2022203504B2 (en) 2025-02-20
AU2022203504A1 (en) 2022-06-09
KR20250081944A (ko) 2025-06-05
EP4043021A3 (en) 2022-11-23
AU2015320665A1 (en) 2017-04-06
EP3198009B1 (en) 2021-09-08
JP6764859B2 (ja) 2020-10-07
CN108064275A (zh) 2018-05-22
US12514887B2 (en) 2026-01-06
JP2021007392A (ja) 2021-01-28
JP2017534263A (ja) 2017-11-24
EP3198009A1 (en) 2017-08-02
KR20230165385A (ko) 2023-12-05
JP2024038030A (ja) 2024-03-19
US20170202893A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
IL251972B (en) Analyzing and utilizing landscapes
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
IL251970B (en) Anti-cd79b antibodies and methods of use
IL254039A0 (en) Anti-pvrig antibodies and methods of use
IL253162A0 (en) Compositions and methods for treatment and detection of cancers
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
EP3198009A4 (en) Oncolytic tumor viruses and methods of use
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
HUE046756T2 (hu) Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
PL3319808T3 (pl) Sposoby wytwarzania dokumentów zabezpieczonych i urządzenia zabezpieczające
DK3221357T3 (da) Fælles letkæder og fremgangsmåder til anvendelse
IL252602B (en) Oral care compositions and methods of use
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3218005T3 (da) Glycan-interagerende forbindelser og anvendelsesfremgangsmåder
LT3341027T (lt) Transfekcijos kompleksai ir jų panaudojimo būdai
PT3319612T (pt) Oxisteróis e métodos de utilização dos mesmos
IL253160B (en) Cancer markers and methods of use thereof
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3233105T3 (da) Hidtil ukendt kombination og anvendelse